Irinotecan Sun

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Sun, is a Topoisomerase I inhibitor presented as a solution for injection for intravenous use. It is indicated for metastatic colorectal cancer and as adjuvant therapy for colon cancer in adult patients. GNH USA supplies Irinotecan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan Sun is a Topoisomerase I inhibitor used in colorectal cancer treatment pathways.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. Adjuvant therapy for colon cancer: reduces risk of disease recurrence after surgical resection. Locally advanced colorectal cancer: may be employed in neoadjuvant protocols to shrink tumors before surgery.

Irinotecan Sun may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness during treatment. - Abdominal cramping: discomfort in the stomach area.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: inflammation of the colon that can be life‑threatening. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hemorrhagic cystitis: bladder inflammation with bleeding. - Cardiotoxicity: rare cardiac dysfunction or arrhythmias.

Before initiating Irinotecan Sun, clinicians should assess patient suitability and monitor for known risks. - Baseline blood counts: obtain complete blood count to detect pre‑existing neutropenia. - Liver function: evaluate hepatic enzymes as impaired function can increase toxicity. - Renal function: adjust monitoring for patients with reduced clearance. - Concomitant medications: review for agents that may exacerbate myelosuppression. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential fetal or infant risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Sun can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce SN‑38 exposure. - Anticholinergic agents (e.g., atropine, scopolamine): increase risk of severe diarrhea. - High‑dose corticosteroids: may potentiate neutropenia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may raise SN‑38 levels. - Warfarin: monitor INR as Irinotecan can affect coagulation. - UGT1A1 polymorphisms: genetic testing may be warranted to adjust dosing.